dc.contributor.author
Posa, Daniela
dc.contributor.author
Pizzulli, Antonio
dc.contributor.author
Wagner, Petra
dc.contributor.author
Perna, Serena
dc.contributor.author
Hofmaier, Stephanie
dc.contributor.author
Matricardi, Paolo Maria
dc.contributor.author
Lau, Susanne
dc.date.accessioned
2018-06-08T10:43:12Z
dc.date.available
2017-11-01T11:56:12.078Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/20959
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-24257
dc.description.abstract
Background Upper and lower airways diseases share in part their pathogenic
mechanisms and frequently occur simultaneously as “United Airway Disease.”
Local treatment with nebulizers delivers anti-symptomatic drugs in either the
upper or the lower airways, according to the particle size generated by the
nebulizer. To our knowledge, no nebulizer combines both application ways. The
aim of this study is to test the efficacy and usability of a new nebulizer
(OMRON A3 complete), generating aerosols with particles diameters of 2-4.5 μm,
4.5-7.5 μm or >7.5 μm, according to the user’s choice. Methods Seventy-seven
patients between 5 and 17 years of age with a diagnosis of rhinitis or asthma
were examined. Oxymetazoline or Salbutamol were prescribed according to best
clinical practice guidelines. Both drugs were administered through the OMRON
A3 Complete nebulizer, with a particle dimension of >7.5 μm to treat nasal
obstruction and 2-4.5 μm for bronchial obstruction. The efficacy of treatment
was assessed by total nasal inspiratory airflow and FEV-1, Tiffeneau index
(FEV1/FVC) and MMEF 25/75 respectively, 10 min before and after treatment.
Symptom improvement and usability were measured by patients’ and doctors’
questionnaires. Results Overall, 77 patients seeking care for acute
respiratory symptoms were assigned to the upper (n = 39) or lower (n = 38)
airways disease group. For symptoms of the upper airways, 92% (95% CI, 77-97%)
of the patients reported subjective improvement, while 87% (95% CI, 73-94%)
did so for the lower airways. The average total nasal inspiratory airflow
improved significantly (p = 0.030) among the patients with upper airways
symptoms, from 275 ml/s (95% CI, 207-342 ml/s) to 359 ml/s (95% CI, 300-419
ml/s) after Oxymetazoline administration. All selected lung function
parameters (FEV1, Tiffeneau Index and MMEF25-75) significantly improved among
the patients with lower airways symptoms after inhalation of Salbutamol (p <
0.001). The nebulizer was assessed as “easy to use” by over 95% of
participants in both groups. Conclusions The OMRON A3 efficiently delivers
anti-symptomatic drugs in both upper and lower airways in a user-friendly way.
This device may be useful to facilitate adherence to a complete treatment of
respiratory symptoms in patients with symptoms of the so-called United Airway
Disease.
en
dc.rights.uri
http://creativecommons.org/licenses/by/4.0/
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit
dc.title
Efficacy and usability of a novel nebulizer targeting both upper and lower
airways
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation
Italian Journal of Pediatrics. - 43 (2017), Artikel Nr. 89
dcterms.bibliographicCitation.doi
10.1186/s13052-017-0400-x
dcterms.bibliographicCitation.url
http://doi.org/10.1186/s13052-017-0400-x
refubium.affiliation
Charité - Universitätsmedizin Berlin
de
refubium.mycore.fudocsId
FUDOCS_document_000000028415
refubium.note.author
Der Artikel wurde in einer reinen Open-Access-Zeitschrift puliziert.
refubium.resourceType.isindependentpub
no
refubium.mycore.derivateId
FUDOCS_derivate_000000009063
dcterms.accessRights.openaire
open access